The global anti-radiation drug market was valued at $3.4B in 2021 and is anticipated to grow at a CAGR of 9.9% from 2022 to 2031, according to a study by Transparency Market Research.
Increase in demand for drugs, such as Prussian Blue, Diethylenetriamine pentaacetate or DTPA, and potassium iodide or KI, to block the concentration and absorption of radioactive iodide in the human thyroid gland propels market growth. Moreover, the threat of nuclear disaster looms over humanity owing to the increasing number of nuclear weapons and warheads in the world. Therefore, a rise in efforts by countries to be prepared for nuclear or radioactive disasters by developing radiation countermeasures is augmenting market development.